Ketamine - onset.to

September 21, 2026

How J&J's Spravato launch created the clinic infrastructure Compass needs for its potential COMP360 psychedelic rollout

biopharmadive.com · Sep 21, 2026 · Jacob Bell

September 15, 2026

FDA reclassifies NRx's generic ketamine amendment from Major to Minor, setting a November review goal after a vial-cap deficiency

behavioralwire.com · Sep 15, 2026 · Editorial Desk

Ketamine Article Industry Policy Safety

FDA’s Psychedelics Public Hearing Draws Broad Support but No Questions from Federal Panel

psychedelicalpha.com · Sep 15, 2026 · Josh Hardman

Psilocybin Ketamine Article Policy +2

September 4, 2026

Federal report urges states to prepare for psychedelic therapy approvals as research examines THC placebos, ketamine seizures, and ibogaine

themicrodose.substack.com · Sep 4, 2026 · Anna Marie Yanny

Psilocybin Ketamine Article Policy +2

September 3, 2026

Psilocin rapidly increases synapse formation in cultured rat neurons, matching ketamine and lithium in a laboratory comparison

psypost.org · Sep 3, 2026 · Karina Petrova

Psilocybin Ketamine Article Clinical +2

August 24, 2026

VA coverage of Spravato for treatment-resistant depression can require up to 50 supervised visits and difficult travel

military.com · Aug 24, 2026 · Brandon Wile

Psilocybin Ketamine Article Clinical +2

What is stopping psychedelic therapy in China? Jennifer Docherty on clinicians, family decision-making, and end-of-life care

themicrodose.substack.com · Aug 24, 2026 · Shayla Love

Psilocybin Ketamine Article Clinical +2

August 21, 2026

An embedded-brain view of psychedelic healing links serotonin 2A signaling, social context, and predictive processing in Johnson's theory of consciousness

themicrodose.substack.com · Aug 21, 2026 · jane c. hu

LSD Psilocybin Consciousness Philosophy +5

August 20, 2026

Big pharma targets psychedelic medicine as patent strategies, drug development costs, and mental health demand reshape a fast-growing commercial market

marketplace.org · Aug 20, 2026

Psilocybin MDMA Business Industry +2

August 10, 2026

Why some people do not respond to psychedelics - receptor biology, metabolism, medication interactions, and set-and-setting all shape psychedelic effects

themicrodose.substack.com · Aug 10, 2026 · Shayla Love

LSD Psilocybin Research Safety +3

July 30, 2026

Neuroscientists find psychedelics may alter brain function through shifts in cortical hierarchy, challenging the idea that stronger global connectivity explains the psychedelic state

psypost.org · Jul 30, 2026 · Eric W. Dolan

LSD Psilocybin Article Consciousness +3

July 27, 2026

Hot weather increases psychedelic risks through dehydration, overheating, and poor judgment, making hydration, cooling, and dose planning central to harm reduction

samwoolfe.com · Jul 27, 2026 · Sam Woolfe

LSD Psilocybin Article HarmReduction +3

July 26, 2026

Psychedelics may influence inflammation, metabolism, immunity, and aging pathways beyond mental health through serotonin signaling and neuroimmune effects

thesporereport.com · Jul 26, 2026 · admin

LSD Psilocybin Article Clinical +5

July 25, 2026

Dr Samuel Lee links ketamine's rapid clinical rise to possible decline, warning that hype, weak standards, and commercial pressures could undermine psychedelic therapy

ecstaticintegration.org · Jul 25, 2026 · Jules Evans

Ketamine Ethics Industry Therapy

July 24, 2026

The Psychedelic Inflection Point: Big Pharma, FDA, and the Next Wave of Brain Medicines

youtube.com · Jul 24, 2026 · Tim Gortman

Psilocybin DMT Podcast Business +4

July 22, 2026

Exclusive report traces why Eli Lilly partnered with atai Life Sciences on a ketamine-inspired pipeline, highlighting deuterated candidates, commercial fit, and strategic timing

illusionconsensus.com · Jul 22, 2026 · Rav Arora

Ketamine Business Industry Therapy

Big Pharma just made its biggest bet yet on psychedelics as major drugmakers and investors move deeper into ketamine, psilocybin, and next-generation mental health treatments

thesporereport.com · Jul 22, 2026 · admin

Psilocybin Ketamine Article Business +2

The deliverable market in psychedelic biotech centers on scalable, approvable treatments rather than broad transformation, shaping which compounds, trials, and care models attract capital

darkmatterpragmatism.substack.com · Jul 22, 2026 · Adam D. Borecky, MD

Psilocybin MDMA Business Industry +2

Psychedelics enter mainstream cancer care discussions as clinicians examine distress relief, end-of-life anxiety, and the evidence needed for safe adoption

cancerletter.com · Jul 22, 2026

Psilocybin MDMA Podcast Clinical +3

July 21, 2026

Q3 2026 psychedelic drug development pipeline bullseye charts map clinical-stage programs, company momentum, and the concentration of targets across indications

psychedelicalpha.com · Jul 21, 2026

LSD Psilocybin Clinical Industry +7

July 20, 2026

Psilocybin on the Verge: Treating Depression at Compass Pathways

youtube.com · Jul 20, 2026 · Dr. Steve Levine

Psilocybin Ketamine Interview Clinical +2

Ibogain bei Ketamin-Gebrauchsstorung - erster dokumentierter Langzeitfall zeigt anhaltende Abstinenz und klinische Verbesserungen nach 18 Monaten

psychedelia-stiftung.de · Jul 20, 2026

Ibogaine Ketamine Article Clinical +2 DE

July 19, 2026

Psychedelic drugs move toward mainstream mental health care as researchers, startups, and regulators test psilocybin, MDMA, and ketamine treatments

cnbc.com · Jul 19, 2026 · Bob Woods

Psilocybin MDMA Mainstream Research +2

July 16, 2026

Psychedelics and adult ADHD draw rising interest, but current evidence remains limited, mixed, and far from establishing a safe or effective treatment approach

thesporereport.com · Jul 16, 2026 · admin

LSD Psilocybin Article Clinical +4

July 8, 2026

Cascades Analytics with Tanya Ramey (Altaïr, Former Usona, Pfizer, NIDA)

youtube.com · Jul 8, 2026 · Cascades Analytics

Psilocybin 5-MeO-DMT Interview Clinical +3